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Objectives: We aimed to investigate whether long-term adherence to a gluten-free diet is related to depres-
sive symptoms in coeliac disease (CD) patients.
Methods: A cross-sectional survey was performed in 2265 adult CD patients recruited through the Dutch
Coeliac Association. Self-reported diet adherence was compared among groups based on self-reported
depressive symptoms (categorized into current [1-month], remitted, and never).
Results: The life-time prevalence rate of self-reported depressive symptoms was 39.0% (n=883), of whom
270 (11.9%) suffered from current depressive symptoms. Adherence to gluten-free diet was strict in 50.2%
of patients, sufﬁcient in 46.3%, and insufﬁcient in 3.6%. Insufﬁcient adherence was not associated with current
depressive symptoms (odds ratio [OR] 0.95; 95% conﬁdence interval [CI]: 0.48–1.92). Keeping a gluten-free
diet for longer than ﬁve years was associated with lower OR of current depressive symptoms compared to
being on a diet for less than two years (OR 0.69; 95% CI: 0.50–0.95).
Conclusions: Lifetime depressive symptoms may be present in one third of the CD patients who adhere to
gluten-free diet. Long-term adherence to the gluten-free diet may reduce the risk of current depressive
symptoms.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Coeliac disease (CD) is an immune-mediated intolerance for glu-
ten in genetically predisposed individuals and is characterized by an
inappropriate immune response of the T-lymphocytes of the small in-
testines to gluten peptides. This results in intestinal malabsorption,
atrophy of the intestinal villi and chronic inﬂammation of the jejunal
mucosa of the small intestine. The clinical presentation varies widely,
as CD is now considered a multisystem disorder affecting multiple
organs, such as the skin, thyroid, heart, nervous system, pancreas,
spleen, liver [1], as well as the brain. CD has a prevalence rate in
Europe and the USA of about 1:100 [2] and is associated with an
increased prevalence of psychopathology [3,4]. The only available
treatment is a strict gluten-free diet (GFD), which leads to restoration
of the atrophied intestinal villi. It may, however, take years to achieve
complete recovery of the intestinal villi [5], and the effects of the diet
on mood and psychiatric symptoms are largely unknown.
Common psychiatric symptoms in untreated CD are depressive
symptoms, apathy, anxiety, and irritability [6–9]. A cross-sectional,
case–control study in 36 CD patients and 144 controls used the
Composite International Diagnostic Interview (CIDI) to assess life-
time psychopathology [7]. They found that the risks of major depres-
sion (MD; 41.7%), dysthymic disorder (8.3%), adjustment disordersen University,Wassenaarseweg
751; fax: +31 71 527 3932.
M. van Hees).
NC-ND license.(30.5%), and panic disorder (13.9%) were increased in CD. Increased
rates of depressive and anxiety symptoms were also found in CD
patients on a GFD [4,10,11]. The reported prevalence of depressive
symptoms in CD patients varies widely across studies, ranging from
6 to 69% [8,12–17]. Differences in patient characteristics, cultural
background, and study design may account for the large variability
[3,18,19]. In a large longitudinal population-based cohort study, CD
patients were at an 80% increased risk of depression compared to
controls [19]. Only one case–control study found equal prevalence
rates of depression (17.2% versus 16%) [20]. However, diagnoses for
depression in this study were solely based on notes from primary
care providers or gastroenterologists and reliability may be questioned.
The increased risk of depressive symptoms in CD patients could be
explained by several mechanisms. Firstly, dietary non-compliance
and sustained malabsorption may play a role [18], which could lead
to sustained nutritional deﬁciencies (e.g. of vitamin B6, vitamin B12,
and folic acid) which in turn may have increased the risk of depres-
sion [21]. Secondly, nutritional deﬁciencies may be a consequence
of the strict restrictive GFD. Many of the gluten-free grains do not
inherently contain thiamin, riboﬂavin, niacin, folate, and iron, nor
are gluten-free food products in general required to be enriched
with these micronutrients by food authorities [22–24]. Whether nu-
tritional deﬁciencies caused by the daily diet in general contribute
to the risk of depression is unknown at this time. There might also
be reductions in brain monoamine availability and metabolism [27]
and regional cerebral hypoperfusion [28] in patients with CD that
may subsequently have induced depression. Thirdly, psychosocial
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patients may avoid social situations which involve eating and also
may experience more psychological distress due to daily hassles,
negative responses to the diet by their social surroundings, and
continued worrying about dietary mistakes and negative health out-
comes [25–28]. Distress, social isolation and loneliness may subse-
quently lead to depression [29]. Fourthly, depression in CD may be
secondary to an association between CD and other auto-immune
diseases that carry a high risk of depression, such as thyroid disease
and diabetes mellitus [7,20].
It is often assumed that dietary non-compliance increases the risk
of depressive symptoms. It is common practice to refer CD patients
to a dietician for a diet review. The literature on the relationship
between adherence to gluten-free diet and depression however is in-
conclusive and long term dietary compliance in relation to depression
has not been studied in depth. Two case series found that psychiatric
disturbances and depressive symptoms improved rapidly after the
introduction of a gluten-free diet [30,31], but several other studies
found no improvement [7,25,32]. One study even reported more
depressive symptoms for GFD-treated versus untreated CD patients
[33]. In addition, one study found a small signiﬁcant correlation
between non-compliance and depressive symptoms [34], one study
found diet adherence not to be a predictor of depressive symptoms
[35], and one study found that strict diet adherence was related to
an increase in depressive symptoms independent from duration of
diet [12]. Most studies included recently diagnosed CD patients and
did not study patients who were on a diet for more than one year,
while the restoration of the absorption function may take two [36]
to ﬁve years [5].
In the present study, we investigated the association of duration
and stringency of the GFD with the prevalence of depressive symp-
toms. We performed a cross-sectional survey on a representative
sample, comparing groups of adult CD patients who report never
having had depressive symptoms, who are remitted from depressive
symptoms or who currently experience depressive symptoms. We
hypothesized that CD patients who adhere badly to the GFD have an
increased risk of currently having depressive symptoms compared
to CD patients who strictly adhere to the GFD. We also expected that
increased length of the GFD is associated with a lower risk of depres-
sive symptoms.
Methods
Patients
Participants were recruited from the 7119 adult members of the
Dutch Coeliac Association (NCV). The NCV comprises CD patients
with varying treatment history and severity of illness. According to
self-report, 87% of this population had the diagnosis of coeliac disease
conﬁrmed by a biopsy of the intestinal lining. In 7% the diagnosis
was made by other means and 5% was on GFD for other medical
reasons [37].
Instruments
Adherence to gluten-free diet
Diet adherence of the GFD was assessed by one self-report reply to
the question: “I keep my diet: very stringent/simply right/moderately
well/not well”. Similar questions and methodology have been used in
other studies [8,28,35,38–41].
Self-reported depressive symptoms
Self-reported current and past depressive symptoms were
assessed with the Major Depression Questionnaire (MDQ) [42], an
18 item self-reported questionnaire which assesses the diagnostic
criteria for MD according to the Diagnostic and Statistical Manual ofMental Disorders, Fourth Edition (DSM-IV-TR) [43] criteria for MD.
A previous validation study in a small sample (n=39) showed excel-
lent sensitivity (100%) and negative predictive value (100%), good
positive predictive value (79%), speciﬁcity (75%) and overall kappa
(0.75), compared with interview-based diagnoses [44]. The MDQ
consists of a series of questions that cover all DSM-IV diagnostic
criteria for current and past major depression [43], including impact
on functioning and exclusion criteria (e.g., mourning). The scoring
criteria and the cut-off for caseness versus noncaseness also follow
DSM-IV, in other words no case of depression is assumed when
both core symptoms of depression are absent or self-reported impact
on functioning is low. This leads to self-reported depressive symp-
toms which can be categorized as MDQ cases and MDQ noncases.
MDQ caseness can be further subdivided in never, remitted and cur-
rent cases. The items that make up a positive caseness score in the
MDQ include an item on changes in quality of sleep and an item on
changes in body weight. As these symptoms may overlap with those
of CD, we made an attempt to exclude themost profound physical con-
sequences of CD through additional instructions and item-wording. Al-
though participants were instructed to disregard the cause of physical
symptoms and just report whether the symptom was present or not,
they were asked to only report weight change achieved without intent
and caused by increased or decreased appetite and only to report sleep
disturbance leading to at least a 2 hour change from usual for most of
the time during a 2 week period.
Symptoms of anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) [45] is a 14
item self-reported questionnaire for the assessment of symptoms of
anxiety and depression with good case-ﬁnding ability. Cronbach's
alpha is .83 for the HADS anxiety scale (HADS-A) and .82 for the
HADS depression scale (HADS-D). The optimal cut-off score is 8 and
the concurrent validity of the HADS was found to be good to very
high [46]. The Dutch version has good internal consistency in medical
outpatients (HADS total score, α=.90). The sensitivity and speciﬁcity
to detect MD with a cut-off point of 8 on the depression subscale
are 56% and 82%, respectively [47]. The HADS is designed to screen
non-psychiatric hospital outpatients for possible anxiety or depres-
sive disorder and items referring to eating and sleep disturbances
are not included in the scale making it a ﬁtting tool for populations
with somatic illness such as CD. It has been suggested in a recent
review that the results of the HADS should be interpreted as a unidi-
mensional measure of “emotional distress” [48] and therefore we
reported both the HADS subscale scores as well as total scores.
Vulnerability to depression
Cognitive vulnerability to depression was measured with the short
(6-item) version of the self-report Leiden Index of Depression Sensi-
tivity (Leids-R-SF), derived from the 34 item Leids-R [49]. The
Leids-R consists of questions like “When I am feeling down, I more
often think about how I am unable to make anyone happy” and “I can
only think positive when I feel well” followed by a ﬁve point Likert
scale. The Leids-R-SF in our sample had good internal consistency
(α=0.87).
Procedure
The questionnaires were bundled in a questionnaire-booklet,
which was sent out as unsolicited mail accompanying a 2007 issue
of the NCV quarterly magazine. The questionnaires were also handed
out during ﬁve NCV events, were made available online, and were an-
nounced on various Dutch CD websites, forums and mailing lists. Ar-
ticles about the questionnaire and the study were published in four
issues of the quarterly magazine and these articles were also made
available through the online questionnaire website. This study was
approved by the ethics committee of the institute of psychology of
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ticipate in the study when returning the completed questionnaire.
Statistical analysis
Records were excluded on the basis of one or more missing values
on the main variables of interest. Data imputation was not performed
in any of the measures except the HADS. Data imputation with case
means per subscale was performed for records with 3 or less missing
values per subscale (n=74, 3.1%). Records with more than 3 missing
values per subscale were excluded (n=14, 0.6%). Patients were cate-
gorized into the three groups (i.e., absent, remitted or current depres-
sive symptoms) based on MDQ scores. Differences between these
study groups were analyzed for socio-demographic characteristics,
comorbid disorders, other depression assessment variables, character-
istics of depressive symptom episodes and dietary habits by analysis
of variance (ANOVA) or Pearson chi-squared (χ2) tests for categorical
variables. Hochberg's GT2 and Games–Howell post-hoc tests were
used, when appropriate. Kruskal–Wallis test (H) was used to assess
length of depressive symptomepisode and length of diet per depression
category. Jonckheere–Terpstra andMann–Whitney post-hoc tests were
used, when appropriate. Associations between GFD characteristics and
current depressive symptomswere analyzed usingmultivariate logistic
regression analysis, which yielded odds ratios (OR) with 95% conﬁ-
dence intervals (CI). Multivariate analyses were adjusted for potential
confounding by age, gender, and level of education (in Model 1) and
additionally for number of other chronic diseases (in Model 2). Statisti-
cal signiﬁcance was inferred at pb .05. All analyseswere donewith SPSS
software (SPSS Inc., Chicago, IL) [50].
Results
Participant ﬂow
In total we received 2407 valid responses (response rate of 33.8%). 1793 partici-
pants returned the paper questionnaire and 614 completed it online. During a brief
interview on the reasons for dropout among 30 subjects, a lack of time was most fre-
quently reported. A small minority indicated never having had depressive symptoms
and therefore thought themselves unsuitable, and others anticipated that participationTable 1
Socio-demographic and medical characteristics of the study patients with coeliac disease a
Total Never
Number of patients—n (%) 2265 1382
Age (years)—mean (SD) 51.8±16.1 54.6±16.1
Gender: n (%)
• Male 556 (24.5%) 419 (30.3%)
• Female 1709 (75.5%) 963 (69.7%)
Level of education: n (%)
• Low 627 (27.7%) 432 (31.3%)
• Intermediate 691 (30.5%) 386 (27.9%)
• High 947 (41.8%) 564 (40.8%)
Comorbidity (% total n):b n (%)
• Cardiovascular disease 110 (4.9%) 66 (4.8%)
• Diabetes mellitus 81 (3.6%) 51 (3.7%)
• Chronic pulmonary disease 168 (7.4%) 91 (6.6%)
• Rheumatoid disease 59 (2.6%) 34 (2.5%)
• Arthrosis 44 (1.9%) 19 (1.4%)
• Hypothyroidism 116 (5.1%) 55 (4%)
• Other thyroid diseases 46 (2%) 34 (2.5%)
• Osteoporosis 123 (5.4%) 72 (5.2%)
• Cancer 42 (1.9%) 23 (1.7%)
• IBD 30 (1.3%) 19 (1.4%)
Number of comorbid disorders:b n (%)
• No comorbidity 1383 (61.1%) 888 (64.3%)
• 1 comorbid disorder 575 (25.4%) 341 (24.7%)
• ≥2 comorbid disorders 307 (13.6%) 153 (11.1%)
Data are presented as n (%) or mean (± SD), when appropriate. IBD denotes Inﬂammatory
a p-Values by chi-squared test for categorical variables and by ANOVA for continuous var
b Comorbidity is self-reported and deﬁned as being diagnosed by a physician.would be too depressing. Records with missing data on the variables age (n=8), level
of education (n=8), gender (n=14), status of GFD (n=2), length of GFD (n=50), total
MDQ (n=50), total HADS (n=14), and dietary adherence (n=51) were excluded from
analysis. Records of CD patients whowere not on a GFD and had not been on a GFD in the
past (patient is in the process of receiving a diagnosis), were also excluded (n=32). The
total number of excluded records was 142 (5.9%).
The total sample therefore consisted of 2265 (94.1%) CD patients. However, some
of these participants had missing data on the variables describing psychiatric charac-
teristics. The sample size was therefore smaller for analyses involving description
of: vulnerability to depression (n=2081); age at ﬁrst depressive symptom onset
(n=2173); number of lifetime depressive symptom episodes (n=2135); and length
of the most severe episode (n=1980).
Patient characteristics
Patients were on average 52 years old (range 18–93 years), 75.5% was female, and
they had above average educational attainment (Table 1). Comorbid disorders were
reported by 882 patients (38.9%), most often mentioned were chronic pulmonary
disease (n=168), osteoporosis (n=123), hypothyroidism (n=116) and cardiovascu-
lar disease (n=110). Table 1 shows the results for 11 comorbid disorders in relation
to depression categories (never, remitted and current). Comorbid chronic pulmonary
disease and hypothyroidism were signiﬁcantly associated with depressive symptom
categories (pb .001 and p=.008, respectively). The results for inﬂammatory bowel
disease (Chron's disease, colitis ulcerosa, collagenous-, lymphocytic-, microcytic colitis)
should be interpreted with some caution since the expected cell count was below ﬁve
for the currently depressed category (n=30, p=.66). Table 1 also shows that there
was an overall effect of number of comorbid diseases on depressive symptoms
(χ2 (4)=30.4; pb .001). Having one comorbid disorder raised the OR of having cur-
rent depressive symptoms compared to having no comorbid disorder (1.43, 95% CI:
1.06–1.93). Having more than one comorbid disorder in addition to CD doubled the
OR of having current depressive symptoms (2.15; 95% CI: 1.54–3.01).
Characteristics of depressive symptoms
The life-time prevalence rate of depressive symptoms (i.e., current plus remitted)
was 39.0% (n=883), of whom 270 (11.9%) suffered from current depressive symp-
toms. Table 1 shows demographic and medical characteristics of CD patients according
to the three depressive symptom categories.
Themean age differed among the three groups (F (2, 2265)=56.7; pb .001). Post-hoc
tests revealed that the group who never experienced depressive symptoms was signiﬁ-
cantly older than the groups with current and remitted depressive symptoms.
The gender distribution also differed among groups (χ2 (2)=63.8; pb .001), driven
by the higher OR of female versus male CD patients in the remitted or current groups
(2.37; 95% CI: 1.91–2.94). The level of education also signiﬁcantly differed among the
groups (χ2 (4)=42.6; pb .001), driven by the higher OR for high versus
low-educated CD patients in the remitted or current groups (3.26; 95% CI: 2.64–4.04).ccording to categories of depressive symptoms
Remitted Current p-Value a
613 270
47.7±15.0 46.6±15.3 b .001
94 (15.3%) 43 (15.9%) b .001
519 (84.7%) 227 (84.1%)
116 (18.9%) 79 (29.3%) b .001
204 (33.3%) 101 (37.4%)
293 (47.8%) 90 (33.3%)
24 (3.9%) 20 (7.4%) .08
18 (2.9%) 12 (4.4%) .50
41 (6.7%) 36 (13.3%) b .001
17 (2.8%) 8 (3%) .85
17 (2.8%) 8 (3%) .49
43 (7%) 18 (6.7%) .008
6 (1%) 6 (2.2%) .09
35 (5.7%) 16 (5.9%) .84
14 (2.3%) 5 (1.9%) .64
9 (1.5%) 2 (0.7%) .66
360 (58.7%) 135 (50%) b .001
157 (25.6%) 77 (28.5%)
96 (15.7%) 58 (21.5%)
Bowel Disease.
iables.
Table 2
Psychiatric characteristics of the study patients with coeliac disease according to categories of depressive symptoms
Total Never Remitted Current p-Value a
Number of patients 2265 1382 613 270
HADS—mean±SD
• HADS Depression 4.5±3.9 3.3±3.2 5.2±3.9 9.2±3.4 b0.001
• HADS Anxiety 6.1±4.0 4.7±3.4 7.3±3.7 10.6±3.3 b0.001
• HADS Total 10.6±7.3 8.0±6.0 12.5±6.9 19.8±5.8 b0.001
Cognitive vulnerability—mean±SD 8.4±5.6 6.3±5.0 10.2±4.7 14.2±4.6 b0.001
First onset of depressive symptomsb—n 791 527 219
• Before introduction of GFD 590 (74.6%) – 424 (74.1%) 166 (75.8%) 0.89
• During the ﬁrst 2 years on GFD 10 (1.3%) – 7 (1.2%) 3 (1.4%)
• During the 2nd to 5th year on GFD 39 (4.9%) – 30 (5.2%) 9 (4.1%)
• After more than 5 years on GFD 152 (19.2%) – 111 (19.4%) 41 (18.7%)
Number of lifetime episodes—Mdn (Q1–Q3) 3.0 (1.0–10.0) 2.0 (1.0–5.8) 8.0 (3.5–20.0) b0.001
Length of most severe episode (years)—Mdn (Q1–Q3) 1.0 (0.5–3.0) 1.0 (0.4–2.5) 2.0 (0.5–5.4) b .03
Data are presented as n (%), mean (± SD) and median (Q1–Q3) when appropriate. HADS denotes the Hospital Anxiety and Depression Questionnaire; GFD, gluten-free diet.
a p-Values based on chi-square test for categorical variables, F-test for continuous variables and Kruskall–Wallis H for non-parametric continuous variables.
b First onset of depressive symptoms was calculated in a smaller sample (n=2173) due to missing data.
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(F (2, 667)=366.2; pb .001), HADS-Anxiety (F (2, 687)=398.6, pb .001), and HADS-Total
(F (2, 688)=496.2, pb .001) symptom scores among the three depressive symptom
groups. Post-hoc tests showed that the mean HADS-D, HADS-A, and HADS-Total scores
differed signiﬁcantly in one-by-one comparisons (all psb .001). The biserial correlation
coefﬁcient between HADS-D scores and the category of current depressive symptoms
deﬁned by MDQ results showed a strong and signiﬁcant correlation (rb=0.71, pb .001).
There was a signiﬁcant overall difference in the mean LEIDS-R-SF scores (H(2)=
357.0, pb .001), and all one-by-one comparisons were signiﬁcant (all psb .001).
Of the 883 CD patients with lifetime depressive symptoms, 74.6% had the onset
of their ﬁrst depressive symptoms before introduction of the GFD (Table 2). Patients
with current depressive symptoms reported more lifetime episodes of depressive
symptoms than patients with remitted depressive symptoms (H(1)=97.0; pb .001),
and they also reported longer episodes (H(1)=4.94; pb .03).
Dietary adherence to the GFD
On average, patients were maintaining a GFD for an uninterrupted period of
8.2 years, ranging between one week and sixty years (Table 3). Length of current
GFD differed signiﬁcantly among the three groups (H(2)=31.80; pb .001). The
Mann–Whitney test showed that duration of the GFD differed signiﬁcantly between
the never and remitted depressive symptom groups (pb .001), as well as between
the remitted and current depressive symptom groups (p=.019), with the shortest
duration of the GFD for the current depressive symptom group.
The dietary adherence categories “moderately well” and “not well”were collapsed
for the purpose of analyses, because of small numbers. There was no signiﬁcant overall
difference in categories of self-reported dietary adherence among the never, remitted
and current groups (χ2 (4)=1.185; p=.89).
Associations between GFD characteristics and depressive symptoms
The associations between GFD characteristics and depressive symptoms are
presented in Table 4. The duration of the GFD related to the three depressive symptom
categories. Although a duration of the GFD of 2 up to 5 years was not signiﬁcantly
associated with a reduced risk of current depressive symptoms, it was decreased in
those CD patients being on a GFD longer than 5 years versus shorter than 2 yearsTable 3
Dietary habits of the study patients according to categories of depressive symptoms
Total N
Number of patients 2265 1
Length of gluten-free diet—Mdn (Q1–Q3) 5.8 (2.3–12.0) 6
Length of present diet
• 0 to 2 years 466 (20.6%) 2
• 2 to 5 years 535 (23.6%) 3
• 5 years and longer 1264 (55.8%) 8
Dietary adherence by self-report: “I keep my diet:”
• Very stringent diet 1136 (50.2%) 6
• Sufﬁcient diet 1048 (46.3%) 6
• Moderately well/not well 81 (3.6%) 4
Data are presented as n (%) or median (Q1–Q3), when appropriate.
a p-Values based on chi-square test for categorical variables and Kruskall–Wallis H for no(adjusted OR: 0.69, 95% CI: 0.50–0.95; Wald χ2(1)=5.28, p=.02). The adherence to
the GFD was not associated with current depressive symptoms in the fully adjusted
model 2 (Wald χ2(1)=0.01, p=.92).Discussion
In our group of 2265 adult CD patients, a lifetime prevalence of
depressive symptom cases of 39% was found, based on MDQ ques-
tionnaire scores. This is in line with previous ﬁndings of high rates
of MD [7] and depressive symptoms [8,25]. Long-term adherence to
the gluten-free diet (over 5 years) was associated with a reduced
risk of current depressive symptoms, which is in line with ﬁndings
from an Italian study [27]. We found no association of self-reported
diet stringency and depressive symptoms in our population, which
is also in line with results found in Italy and Germany [8,35].Why is the prevalence of depressive symptoms increased in CD?
The one-month and lifetime prevalences of depressive symptom
cases based on MDQ questionnaire scores observed in our study
(i.e., 11.8% and 39.0%, respectively) appear to be higher than the rates
of MD in the general Dutch population (2.7% and 15.4%, respectively)
[51]. CD patients with current depressive symptoms also reported
increased anxiety symptoms. This may be due to the well-established
relationship between anxiety and mood disorders and the overlap
between anxiety and depressive symptoms, or may signal an indepen-
dent association between anxiety disorders and CD [4,7,10,25,35].
Cognitive vulnerability to depression scores were also increased in CD
patients with remitted and current depressive symptoms [49].ever Remitted Current p-Value a
382 613 270
.4 (2.8–12.9) 5.0 (2.0–11.3) 4.0 (1.5–10.0) b .001
48 (17.9%) 144 (23.5%) 74 (27.4%) b .001
07 (22.2%) 154 (25.1%) 74 (27.4%)
27 (59.8%) 315 (51.4%) 122 (45.2%)
87 (49.7%) 306 (49.9%) 143 (53.0%) .89
47 (46.8%) 284 (46.3%) 117 (43.3%)
8 (3.5%) 23 (3.8%) 10 (3.7%)
n-parametric continuous variables.
Table 4
Associations between the characteristics of the gluten-free diet and depressive
symptoms
Length of gluten-free diet
b2 years 2–5 years ≥5 years
Total number of patients 466 535 1264
No. with current
symptoms—n (%)
74 (15.9%) 74 (13.8%) 122 (9.7%)
- Crude association 1.0 (ref) 0.85 (0.60–1.21) 0.56 (0.42–0.77)c
- Model 1a 1.0 (ref) 0.93 (0.65–1.32) 0.68 (0.49–0.93)c
- Model 2b 1.0 (ref) 0.94 (0.66–1.34) 0.69 (0.50–0.95)c
Dietary adherence by self-report
Very stringent
diet
Sufﬁcient diet Insufﬁcient or no
real diet
Total number of patients 1136 1048 81
No. with current
symptoms—n (%)
143 (12.6%) 117 (11.2%) 10 (12.3%)
- Crude association 1.0 (ref) 0.87 (0.67–1.13) 0.98 (0.49–1.94)
- Model 1a 1.0 (ref) 0.84 (0.65–1.10) 0.94 (0.47–1.89)
- Model 2b 1.0 (ref) 0.89 (0.68–1.16) 0.95 (0.48–1.92)
Odds ratios are presented (with 95% conﬁdence intervals).
a Adjusted for age, gender, and level of education.
b Additionally adjusted for number of comorbid chronic diseases.
c pb0.05.
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to the GFD increases the risk of depressive symptoms in CD patients
[8,19]. This was not supported by our data. However, only 3.8% of
our patients kept an insufﬁcient diet, which limited the power to
detect any effects of insufﬁcient dietary adherence. The high preva-
lence of depressive symptoms may also be explained by a general
burden of suffering from a chronic disease [17,26,28,35,52]. Finally,
depression and CD may share underlying biological causal factors,
similar to the link between depression and cardiovascular diseases
that may be explained by underlying atherosclerotic and inﬂamma-
tory processes [53].
We also tested the hypothesis that a longer duration of the GFD is
linked to a lower risk of depressive symptoms. This was supported by
our ﬁndings, but only after more than ﬁve years of keeping a GFD.
This may be a consequence of restoration of the intestinal lining [5]
and a subsequent general improvement in health, which may take
several years [54,55]. Continuing malabsorption problems, which
take longer to dissipate than previously assumed, may induce depres-
sive symptoms.
Strengths and limitations of this study
By using the survey methodology we were able to investigate
a large sample of patients with CD representative of the NCV mem-
bership [37]. The response rate was a satisfactory 34% [37]. The sam-
ple was largely representative of the entire CD population, which in
most studies was found to be skewed towards women and people
with higher education [27,56]. Only 3.8% of our patients reported
keeping an insufﬁcient diet. Nevertheless, it is possible that poor
adherence to the GFD was underreported as participants may tend
to give socially desirable answers. Although assessment of GFD
adherence by a specialized dietician is the most reliable instrument
[40], self-report ratings of dietary adherence have been used in a
range of studies in adults and children with CD. A French study
found higher rates of non-compliance and dietary mistakes (28%)
using an estimated intake of 18 g gluten in 2 months as a cut-off.
Direct enquiries by experts uncovered more frequent occasional
lapses of gluten intake [57]. In a study in which participants were
interviewed by an expert, 7% transgressed at least once a week [27].
Another study using a four-point scale on a self-report survey showed
that 8% of participants adhered to the GFD rarely to sometimes[27,28]. Comparisons among studies are difﬁcult, however, because
of differences in cut-off points for compliance, and more agreement
and guidelines on this matter are needed.
Our study was limited by the cross-sectional design. A potential
source of bias is the reliance on self-report questionnaires. We used
self-report questionnaires for CD diagnoses and for psychiatric diag-
noses, rather than medical ﬁle analysis or structured interviews.
Although attempts have been made to exclude the most profound
physical symptoms of CD that overlap with depressive symptoms,
a self-report survey is not a suitable instrument for accurately dif-
ferentiating between these symptoms. In addition, the MDQ should
be validated more extensively. The HADS on the other hand has been
extensively validated, although some debate has recently arisen on its
subscales [58]. We focused in our survey on depressive symptoms as
these were found to be prevalent in CD [8,25], the risk of other forms
of psychopathology may also be increased [7].
Clinical implications and future research
Depressive symptom rates were found to be high in CD patients.
Depressed CD patients may beneﬁt from available treatments for
depression in addition to the GFD. In turn, improving depressive
symptoms in CD patients may improve these patients' adherence
to the GFD [59] as depression is a risk factor for non-adherence to
medical advice and subsequent poor outcomes [60,61].
Future prospective studies and trials are needed to conﬁrm the
beneﬁcial effects of long-term adherence to the gluten-free diet on
depressive symptoms and MD. Prospective studies—with prolonged
follow-up spanning at least ﬁve years—may help to unravel the time
sequence between changes in the GFD habits and the onset and re-
mission of depressive symptoms and MD.
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